Kyruus Named Winner of the Powerhouse Healthcare Company Category at New England Venture Capital Association’s 2020 NEVY Awards NEVY Award 2020 BOSTON — December 8, 2020— Recently, in homes all over New England, the New England Venture Capital Association (NEVCA)...
HARPOON THERAPEUTICS REPORTS CLINICAL PROGRESS ACROSS ALL FOUR TRITAC® PIPELINE DEVELOPMENT PROGRAMS HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing...
Neurana Pharmaceuticals Announces First Patient Enrolled in Phase 3, RESUME-1 Study SAN DIEGO, Calif., December 21, 2020 — Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that the first...
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program – Financing Round Led by Viking Global Investors – – Proceeds will fund ongoing clinical development of EDG-5506, a novel, oral drug candidate...
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem –First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved– –Potential Approval Q3 2021 with Priority...
First-In-Human Data Supporting the Safety of Glympse Bio’s Biosensors are Presented at the AASLD 2020 Annual MeetingNoninvasive biosensors are developed for the detection and monitoring of NASH CAMBRIDGE, Mass., Nov. 13, 2020 – Glympse Bio (Glympse), a biotechnology...
Recent Comments